Table 2.
Patient characteristics and the prevalence of DTC and apoptotic (M30-positive) tumor cells
| |
DTC |
Apoptotic tumor cells |
||
|---|---|---|---|---|
| n /total (%) | P value | n /total (%) | P value | |
|
Total |
167/400 (42) |
|
89/308 (29) |
|
|
Menopausal status |
|
|
|
|
| Premenopausal |
100/229 (44) |
|
54/176 (31) |
|
| Postmenopausal |
67/171 (39) |
0.368 |
35/132 (27) |
0.425 |
|
Histology |
|
|
|
|
| Invasive ductal |
130/324 (40) |
|
81/258 (31) |
|
| Invasive lobular |
32/66 (49) |
|
7/44(16) |
|
| Other |
2/6 (33) |
|
0/3 (0) |
|
| Missing |
3/4 (75) |
0.418d |
1/3 (33) |
0.060d |
|
Tumor grade |
|
|
|
|
| Grade 2 |
105/260 (40) |
|
51/197 (26) |
|
| Grade 3 |
56/120 (47) |
|
32/94 (34) |
|
| Missing |
6/20 (30) |
0.249d |
6/17 (35) |
0.150 d |
|
Tumor size before NACT |
|
|
|
|
| cT1-2 |
88/208 (42) |
|
46/167 (28) |
|
| cT3-4 |
78/177 (41) |
|
40/128 (31) |
|
| Missing |
6/15 (40) |
0.833 d |
3/13 (23) |
0.488 d |
|
Nodal status before NACT |
|
|
|
|
| cN0 |
41/106 (39) |
|
14/75 (19) |
|
| cN1 |
115/270 (43) |
|
70/213 (33) |
|
| Missing |
11/24 (26) |
0.488 d |
5/20 (25) |
0.020 d |
|
Tumor size after NACT |
|
|
|
|
| ypT0 |
32/90 (36) |
|
25/74 (34) |
|
| ypT1 |
67/169 (40) |
|
40/133 (30) |
|
| ypT2-4 |
68/141 (48) |
0.125 |
24/101 (24) |
0.325 |
|
Nodal status after NACT |
|
|
|
|
| ypN0 |
76/197 (39) |
|
43/149 (29) |
|
| ypN1-3 |
91/203 (45) |
0.205 |
46/159 (29) |
0.989 |
|
ER status |
|
|
|
|
| Negative |
67/147 (46) |
|
42/118 (36) |
|
| Positive |
100/253 (40) |
0.237 |
47/190 (25) |
0.041 |
|
PR status |
|
|
|
|
| Negative |
67/137 (49) |
|
43/105 (41) |
|
| Positive |
100/263 (38) |
0.036 |
46/203 (23) |
0.001 |
|
HER2 status |
|
|
|
|
| Negative |
133/306 (43) |
|
69/237 (29) |
|
| Positive |
34/94 (36) |
0.210 |
20/71 (28) |
0.878 |
|
Response to NACT |
|
|
|
|
| Responderb |
156/373 (42) |
|
87/285 (31) |
|
| Nonresponderc |
11/27 (41) |
0.912 |
2/23 (9) |
0.026 |
|
Pathologic remission |
|
|
|
|
| pCR |
26/75 (35) |
|
18/60 (30) |
|
| No pCR |
141/325 (43) |
0.168 |
71/248 (29) |
0.833 |
|
HER2-directed NACT
a
|
|
|
|
|
| No |
24/68 (35) |
|
8/48 (17) |
|
| Yes | 10/26 (39) | 0.775 | 12/23 (52) | 0.002 |
NACT, neoadjuvant systemic therapy. aOnly HER2-positive patients were taken into account. bpCR or partial response. cStable or progressive disease.
dP value (χ2 test) not including missing data.